Showing 1672 results
-
Press release /Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services…
-
Press release /Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1…
-
Press release /Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months…
-
Press release /Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…
-
Press release /Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
-
Press release /Basel, December 6, 2021 — The bilateral transaction between Novartis and Roche for the sale of 53.3 million (approximately 33%) Roche bearer shares has successfully closed today, December 6, 2021.…
-
Press release /Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms.…
-
Story /Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.
-
Press release /Patients reported prolonged maintenance of global health status[1](overall health) Longer time to deterioration (TTD) seen across multiple clinically relevant symptom categories including…
-
Press release /New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…